Rechargeable Implantable Thin-Film Lithium Battery

可充电植入式薄膜锂电池

• 批准号: 7325861
• 负责人: Simon K Nieh
• 金额: $ 19.38万
• 依托单位: FRONT EDGE TECHNOLOGY, INC.
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-07-13 至 2008-07-12
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7325861
• 关键词: Abdominal Cavity; Adoption; American; Ants; Artificial cardiac pacemaker; Bathing; Caliber; Carbon; Cathodes; Cells; Cellular Phone; Cephalic; Ceramics; Characteristics; Charge; Clinical; Cochlear Implants; Condition; Consensus; Cosmetics; Coupling; Daily; Data; Defibrillators; Dependence; Deposition; Development; Devices; Disadvantaged; Doctor of Medicine; Dose; Ear; Electrolytes; Electromagnetic Energy; Electromagnetics; Electronics; Epilepsy; Extravasation; Film; Goals; Government; Head; Hearing Aids; Heating; Hour; Housing; Image; Implant; Individual; Industry; Infection; Intellectual Property; Iodine; Ions; Legal patent; Letters; Licensing; Life; Light; Link; Liquid substance; Literature; Lithium; Maintenance; Manufacturer Name; Marketing; Measures; Medical; Metals; Nose; Obesity; Obsessive-Compulsive Disorder; Operative Surgical Procedures; Pacemakers; Pain; Parkinson Disease; Patients; Performance; Persons; Pharmaceutical Preparations; Pharyngeal structure; Phase; Positioning Attribute; Power Sources; Process; Prosthesis; Pump; Purpose; Quality of life; Range; Research; Risk; Safety; Sales; Side; Site; Skin; Societies; Solid; Speech; Sports; Swimming; System; Techniques; Technology; Testing; Therapeutic; Thesauri; Thick; Time; Today; Tremor; Universities; Work; chronic depression; chronic pain; commercial application; compliance behavior; cost; day; design; electric impedance; energy density; evaluation/testing; implantable device; improved; manufacturing process; neurosurgery; new technology; particle; professor; programs; seal; size; solid state; vapor

DESCRIPTION (provided by applicant): Battery-powered implantable systems are now being used in a wide array of therapeutic and prosthetic applications such as cardiac pacemakers/defibrillators, drug pumps, and more recently, neurostimulators for Parkinson's, pain relief, and cochlear implants. For most of these applications, the energy-density and life of currently-available batteries is insufficient to enable fully-implantable systems, and the battery power supply must remain external. In Phase I of the proposed program, we intend to demonstrate that a new battery technology, thin-film rechargeable lithium, will enable fully-implantable systems, by demonstrating the feasibility for one particular application: a cochlear implant. This will require that we demonstrate the feasibility of achieving an energy-density of 500mWh/cc (3X to 4X current implantable rechargeable batteries), a 20-year life (5X to 10X current batteries), a 5- or 10-minute recharge capability (not available in current batteries), and improved safety (by using all solid-state battery materials, thereby eliminating the toxic liquid electrolyte in current batteries). In Phase I, we will fabricate individual battery cells and conduct tests to demonstrate these performance capabilities. In Phase II, we will complete the battery by stacking cells within a hermetically- sealed case, and produce a sufficient quantity of batteries for extensive in-house testing and evaluation by a major cochlear-implant manufacturer. Proposed Commercial Applications: Our initial battery will be designed for cochlear implants, which have current annual sales of approximately $ 425 million and expected to grow by approximately 20% annually. Upon completion of the cochlear demonstration battery, we will pursue the other implantable neuromodulation applications, which have current annual sales of $1.6 billion and expected to grow to $10 billion in 10 to 15 years. In addition to neuromodulation applications, our battery technology will be suitable for rechargeable batteries for hearing aids, currently estimated to be a $5 billion dollar industry. Thesaurus Terms: Implantable medical power source, thin-film battery, lithium battery, cochlear implant, neurostimulator power source, neuromodulation implant battery, hearing aid battery. Implantable battery-powered systems are increasingly being used for treating a wide array of neuromodulation applications including cochlear implants, neurostimulation for treating Parkinson's disease, tremors, epilepsy, chronic depression, chronic pain, obesity, angina, obsessive-compulsive disorder, and implantable drug pumps which deliver small precisely controlled doses of drugs directly to targeted sites in the body. For many applications, the energy-density and life of currently-available batteries is inadequate to enable fully-implantable neuromodulation systems. NanoEnergy(r), Front Edge Technology's (FET) novel, rechargeable, thin-film, lithium battery is enabling technology for the successful introduction of fully implantable neuromodulation devices.

描述（由申请人提供）：电池供电的可植入系统现在广泛用于治疗和假肢应用，如心脏起搏器/除颤器，药物泵，以及最近用于帕金森病，疼痛缓解和耳蜗植入的神经刺激器。对于大多数此类应用，目前可用电池的能量密度和寿命不足以实现完全植入式系统，并且电池电源必须保持在外部。在计划的第一阶段，我们打算展示一种新的电池技术，薄膜可充电锂，将实现完全植入式系统，通过展示一个特定应用的可行性：人工耳蜗。这将要求我们证明实现500mWh/cc的能量密度（3X到4X电流的可植入充电电池）的可行性，20年的寿命（5X到10X电流的电池），5或10分钟的充电能力（目前的电池不具备），以及提高安全性（通过使用所有固态电池材料，从而消除目前电池中的有毒液体电解质）。在第一阶段，我们将制造单个电池单元并进行测试以证明这些性能。在第二阶段，我们将把电池堆在一个密封的盒子里，并生产足够数量的电池，供一家主要的人工耳蜗制造商进行广泛的内部测试和评估。拟议的商业应用：我们最初的电池将设计用于耳蜗植入，目前耳蜗植入的年销售额约为4.25亿美元，预计每年将增长约20%。在完成人工耳蜗示范电池后，我们将继续研究其他植入式神经调节应用，这些应用目前的年销售额为16亿美元，预计在10到15年内将增长到100亿美元。除了神经调节应用，我们的电池技术将适用于助听器的可充电电池，目前估计这是一个价值50亿美元的产业。主题词：植入式医疗电源，薄膜电池，锂电池，人工耳蜗，神经刺激器电源，神经调节植入电池，助听器电池。植入式电池供电系统越来越多地用于治疗广泛的神经调节应用，包括耳蜗植入，神经刺激治疗帕金森病，震颤，癫痫，慢性抑郁症，慢性疼痛，肥胖，心绞痛，强迫症，以及植入式药物泵，将小剂量精确控制的药物直接输送到体内的目标部位。对于许多应用，目前可用的电池的能量密度和寿命不足以实现完全植入式神经调节系统。前沿技术公司（Front Edge Technology， FET）的新型可充电薄膜锂电池NanoEnergy(r)为成功引入完全植入式神经调节装置提供了技术支持。